Japan-based Sumitomo Pharma Co., Ltd (TYO: 4506) has announced an expanded Contract Sales Organization (CSO) collaboration agreement with Shanghai Pharmaceuticals Holding Co., Ltd (SHA: 601607; SPH). This new agreement follows the success of their initial collaboration in 2020 and aims to further enhance the co-marketing efforts for prescription drugs.
Building on Previous Success with Almarl in Hypertension Therapy
The first collaboration between the two companies was centered on the hypertension therapy Almarl (Arotinolol) in China. The positive outcomes from this initial partnership have paved the way for a deeper co-marketing strategy, which will now include a broader range of prescription drugs.
Advantages of the CSO Collaboration for Both Parties
The CSO collaboration is expected to provide mutual benefits for both Sumitomo Pharma and Shanghai Pharmaceuticals. By pooling resources and expertise, the companies aim to improve market penetration and patient access to their prescription medications. This strategic move is likely to strengthen their competitive position in the pharmaceutical market.-Fineline Info & Tech
